Advertisement

Liver Diseases pp 427-441 | Cite as

Noninvasive Biomarkers for Liver Fibrosis

  • Gamal Shiha
  • Nasser Mousa
Chapter

Abstract

Fibrosis is a serious problem of chronic liver diseases. Liver fibrosis occurs as a response to different causes of chronic liver diseases. The diagnosing of the degree of liver fibrosis is an essential step in the assessment of the severity of the liver disease and is important for better patient care. The reference method for diagnosis and staging of liver fibrosis is liver biopsy, but it is invasive with many complications and limitations. Up to date, many non-invasive direct or indirect serum markers representing the activity of fibrogenesis have been developed. The direct biomarkers are a mirror of extracellular matrix turnover and indirect markers reflect the hepatocellular dysfunction. These markers may be used single or, in conjugation with each other. The major objective of this review is to understand the diagnostic accuracy, advantages and disadvantages of non-invasive biomarkers and scoring systems currently being used for studying liver fibrosis.

Keywords

Liver fibrosis Noninvasive serum markers Liver biopsy Extracellular matrix 

References

  1. 1.
    Rojkind M, Greenwel P. The extracellular matrix and the liver. In: Arias IM, Boyer JL, Fausto N, et al., editors. The liver: biology and pathology. 3rd ed. New York, NY: Raven Press; 1994. p. 843–68.Google Scholar
  2. 2.
    Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011;25(2):195–206.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest. 2007;117:539–48.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6:425–56.PubMedCrossRefGoogle Scholar
  5. 5.
    Baranova A, Lal P, Birerdinc A, Younossi M. Noninvasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:article 91.PubMedCrossRefGoogle Scholar
  6. 6.
    Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–18.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Wake K. Structure of the sinusoidal wall in the liver. In: Wisse E, Knook DL, Wake K, editors. Cells of the hepatic sinusoid. Leiden: The Kupffer Cell Foundation; 1995. p. 241–6.Google Scholar
  8. 8.
    Bioulac-Sage P, Lafon ME, Saric J, et al. Nerves and perisinusoidal cells in human liver. J Hepatol. 1990;10:105–12.PubMedCrossRefGoogle Scholar
  9. 9.
    Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol. 2007;22(Suppl):S73–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Schuppan D, Afdhal N. Liver cirrhosis. Lancet. 2008;371(9615):838–51.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Bedossa P, Paradis V. Liver extracellular matrix in health and disease. J Pathol. 2003;200:504–15.PubMedCrossRefGoogle Scholar
  12. 12.
    Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000;275:2247–50.PubMedCrossRefGoogle Scholar
  13. 13.
    Schaffner H, Popper H. Capillarization of the sinusoids. Gastroenterology. 1963;44:339–42.CrossRefGoogle Scholar
  14. 14.
    Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol. 2004;40:860–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med. 2000;124:1599–607.PubMedGoogle Scholar
  16. 16.
    Scott LF. Hepatic fibrosis. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Schiff ‘s diseases of the liver. 11th ed. Singapore: Wiley-Blackwell; 2012. p. 297–305.Google Scholar
  17. 17.
    Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ. 2003;10(Suppl 1):S59–67.PubMedCrossRefGoogle Scholar
  18. 18.
    Guo J, Friedman SL. Hepatic fibrogenesis. Semin Liver Dis. 2007;27:413–26.PubMedCrossRefGoogle Scholar
  19. 19.
    Sun J. Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells. J Signal Transduct. 2010;2010:985132.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Grigorescu M. Noninvasive biochemical markers of liver fibrosis. J Gastrointestin Liver Dis. 2006;15:149–59.PubMedGoogle Scholar
  21. 21.
    Murawaki Y, Ikuta Y, Idobe Y, Kawasaki H. Serum matrix metalloproteinase −1 in patients with chronic viral hepatitis. J Gastroenterol Hepatol. 1999;14(2):138–45.PubMedCrossRefGoogle Scholar
  22. 22.
    Boeker KHW, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis. Clin Chim Acta. 2002;316(1–2):71–81.PubMedCrossRefGoogle Scholar
  23. 23.
    Badra G, Lotfy M, El Refaie A, et al. Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis patients. Acta Microbiol Immunol Hung. 2010;57(1):29–42.PubMedCrossRefGoogle Scholar
  24. 24.
    Zhang BB, Min C, Weng HL, et al. Diagnostic value of platelet derived growth factor-BB, transforming growth factor α1, matrix metalloproteinase −1 in serum and peripheral blood mononuclear cells for hepatic fibrosis. World J Gastroenterol. 2003;9(11):2490–6.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis. 2001;21:351–72.PubMedCrossRefGoogle Scholar
  26. 26.
    McGuire RF, Bissell DM, Boyles J, Roll FJ. Role of extracellular matrix in regulating fenestrations of sinusoidal endothelial cells isolated from normal rat liver. Hepatology. 1992;15:989–97.PubMedCrossRefGoogle Scholar
  27. 27.
    Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol. 2006;12:3682–94.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68 276 biopsies. J Hepatol. 1986;2:165–73.PubMedCrossRefGoogle Scholar
  29. 29.
    Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl 1):74–81.PubMedCrossRefGoogle Scholar
  30. 30.
    Moorman A, Gordon S, Rupp L, et al. Base line characteristics and mortality among people in care for chronic hepatitis: the chronic hepatitis cohort study. Clin Infect Dis. 2012;56(1):40–50.PubMedCrossRefGoogle Scholar
  31. 31.
    Cainelli F. Liver diseases in developing countries. World J Hepatol. 2012;4(3):66–7.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Bravo A, Sheth G, Chopra S. Liver biopsy. N Engl J Med. 2001;344(7):495–500.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Zhou K, Lu LG. Assessment of fibrosis in chronic liver diseases. Dig Dis. 2009;10:7–14.CrossRefGoogle Scholar
  34. 34.
    Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol. 2005;42(Suppl 1):S22–36.PubMedCrossRefGoogle Scholar
  35. 35.
    Morling J, Guha I. Biomarkers of liver fibrosis. Clin Liver Dis. 2016;7(6):139–42.CrossRefGoogle Scholar
  36. 36.
    Grigorescu M. Noninvasive biochemical markers of liver fibrosis. J Gastrointestinal Liver Dis. 2006;15:149–59.Google Scholar
  37. 37.
    Baranova A, Lal P, Birerdinc A, et al. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Pradat P, Alberti A, Poynard T, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology. 2002;36(4):973–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Prat D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137(1):1–9.CrossRefGoogle Scholar
  40. 40.
    Akbar Hand Fallatah H. Serum ALT levels in a cohort of healthy blood donors and volunteers from Saudi Arabia: the influence of sex and body mass index. Ann Gastroenterol Hepatol. 2010;1:13–9.Google Scholar
  41. 41.
    Haukeland J, Schreiner L, Lorgen I, Oskar Frigstad S, Bang C, Raknerud N. ASAT/ALAT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis. Scand J Gastroenterol. 2008;43(10):1241–8.PubMedCrossRefGoogle Scholar
  42. 42.
    McPherson S, Stewart F, Henderson E, Burt A, Day C. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59(9):1265–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med. 2003;163(2):218–24.PubMedCrossRefGoogle Scholar
  44. 44.
    Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol. 2007;13(4):525–31.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Shiha G, Mousa N, Salah M, Soliman R, Abed S, Elbasiony M, et al. Noninvasive markers for staging fibrosis in chronic hepatitis B patients. Med J Viral Hepat. 2018;2(2):17–23.Google Scholar
  46. 46.
    Green R, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123:1367–84.PubMedCrossRefGoogle Scholar
  47. 47.
    Wai C, Greenson J, Fontana R, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–26.PubMedCrossRefGoogle Scholar
  48. 48.
    da Silva JR, Fakhouri R, Do-Nascimento T, Santos I, Barbosa L. Aspartate aminotransferase to-platelet ratio index for fibrosis and cirrhosis prediction in chronic hepatitis C patients. Braz J Infect Dis. 2008;12(1):15–9.PubMedGoogle Scholar
  49. 49.
    Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-C’ardenas E, S’anchez-Avila F, Vargas-Vor’ackov’a F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol. 2008;7(4):350–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Chrysanthos N, Papatheodoridis G, Savvas S, et al. Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol. 2006;18(4):389–96.PubMedCrossRefGoogle Scholar
  51. 51.
    Lok A, Ghany M, Goodman Z, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005;42(2):282–92.PubMedCrossRefGoogle Scholar
  52. 52.
    Toniutto P, Fabris C, Bitetto D, et al. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol Hepatol. 2007;22(11):1904–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Toson SA, Shiha GE, El-Mezayen HA, El-Sharkawy AM. Diagnostic performance of T lymphocyte subpopulations in assessment of liver fibrosis stages in hepatitis C virus patients: simple noninvasive score. Eur J Gastroenterol Hepatol. 2016;28(8):931–9.CrossRefGoogle Scholar
  54. 54.
    Croquet V, Vuillemin E, Ternisien C, et al. Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol. 2002;14:1133–41.PubMedCrossRefGoogle Scholar
  55. 55.
    Pilette C, Oberti F, Aubé C, et al. Non-invasive diagnosis of esophageal varices in chronic liver diseases. J Hepatol. 1999;31:867–73.PubMedCrossRefGoogle Scholar
  56. 56.
    Kim BK, Kim DY, Park JY, Ahn SH, Chon CY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010;30:546–53.PubMedCrossRefGoogle Scholar
  57. 57.
    Yang HR, Kim HR, Kim MJ, Ko JS, Seo JK. Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. World J Gastroenterol. 2012;18(13):1525–30.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Mallet V, Dhalluin-Venier V, Roussin C, et al. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2009;29(4):409–15.PubMedCrossRefGoogle Scholar
  59. 59.
    Shiha G, Seif S, Eldesoky A, Elbasiony M, Soliman R, Metwally A. A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C. Hepatol Int. 2017;11(3):286–91.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Angulo P, Hui J, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:847–54.CrossRefGoogle Scholar
  61. 61.
    Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104–12.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Koda M, Matunaga Y, Kawakami M, et al. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology. 2007;45(2):297–306.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Halfon P, Penaranda G, Renou C, et al. External validation of FibroIndex. Hepatology. 2007;46(1):280–1.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004;3:8.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Poynard T, Munteanu M, Deckmyn O, et al. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. J Hepatol. 2012;2012(57):541–8.Google Scholar
  66. 66.
    Cales P, Veillon P, Konate A, et al. Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem. 2008;41:10–8.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem. 2004;50:1344–55.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology. 2006;43:S113–20.PubMedCrossRefGoogle Scholar
  69. 69.
    Salkic NN, Jovanovic P, Hauser G, Brcic M. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: A meta-analysis. Am J Gastroenterol. 2014;109(6):796–809.PubMedCrossRefGoogle Scholar
  70. 70.
    Munteanu M, Ratziu V, Morra R, et al. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J Gastrointestin Liver Dis. 2008;17:187–91.PubMedGoogle Scholar
  71. 71.
    Mousa N, Abdel-Razik A, Sheta T, Shabana W, Zakria Z, Awad M, et al. Serum Leptin and Homeostasis Model Assessment-IR as a novel predictor of early liver fibrosis among patients with chronic hepatitis B virus infection. Br J Biomed Sci. 2018;75(4):192–6.PubMedCrossRefGoogle Scholar
  72. 72.
    Abdel-Razik A, Mousa N, Besheer TA, Eissa M, Elhelaly R, Arafa M, El-Wakeel N, Eldars W. Neutrophil to lymphocyte ratio as a reliable marker to predict insulin resistance and fibrosis stage in chronic hepatitis C virus infection. Acta Gastroenterol Belg. 2015;78(4):386–92.PubMedGoogle Scholar
  73. 73.
    Poynard T, Aubert A, Bedossa P, et al. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology. 1991;100(5):1397–402.PubMedCrossRefGoogle Scholar
  74. 74.
    Nguyen-Khac E, Chatelain D, Tramier B, et al. Assessment of asymptomatic liver fibrosis in alcoholic patients using FibroScan: prospective comparison with seven non-invasive laboratory tests. Aliment Pharmacol Ther. 2008;28:1188–98.PubMedCrossRefGoogle Scholar
  75. 75.
    Oberti F, Valsesia E, Pilette C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology. 1997;113:1609–16.PubMedCrossRefGoogle Scholar
  76. 76.
    Forns X, Ampurdanes S, Llovet J, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986–92.PubMedCrossRefGoogle Scholar
  77. 77.
    Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867–73.PubMedCrossRefGoogle Scholar
  78. 78.
    Huang Y, Adams LA, Joseph J, Bulsara MK, Jeffrey GP. The ability of Hepascore to predict liver fibrosis in chronic liver disease: a meta-analysis. Liver Int. 2017;37:121–31.PubMedCrossRefGoogle Scholar
  79. 79.
    Abdel-Razik A, Mousa N, Shabana W, Refaey M, El Mahdy Y, Elhelaly R, Elzehery R, Zalata K, Arafa M, Elbaz S, Hafez M, Awad M. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study. Eur J Gastroenterol Hepatol. 2016;28(1):e1–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Calès P, Boursier J, Oberti F, Hubert I, Gallois Y, Rousselet M, et al. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterol Clin Biol. 2008;32(6 Suppl 1):40–51.PubMedCrossRefGoogle Scholar
  81. 81.
    Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, et al. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Aliment Pharmacol Ther. 2016;44(8):877–89.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Compar Hepatol. 2005;4:Article 10.CrossRefGoogle Scholar
  83. 83.
    Lassailly G, Caiazzo R, Hollebecque A, Buob D, Leteurtre E, Arnalsteen L, et al. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. Eur J Gastroenterol Hepatol. 2011;23(6):499–506.PubMedCrossRefGoogle Scholar
  84. 84.
    Callewaert N, Vlierberghe HV, Hecke AV, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med. 2004;10:429–34.PubMedCrossRefGoogle Scholar
  85. 85.
    Younossi ZM, Baranova A, Stepanova M, Page S, Calvert VS, Afendy A, Goodman Z, Chandhoke V, Liotta L, Petricoin E. Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis. J Proteome Res. 2010;9(6):3218–24.PubMedCrossRefGoogle Scholar
  86. 86.
    Baranova A, Lal P, Birerdinc A, Younossi Z. Noninvasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:Article 92.CrossRefGoogle Scholar
  87. 87.
    Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293–302.PubMedCrossRefGoogle Scholar
  88. 88.
    Tamura H, Matsuda A, Kidoguchi N, Matsumura O, Mitarai T, Isoda K. A family with two sisters with collagenofibrotic glomerulonephropathy. Am J Kidney Dis. 1996;27(4):588–95.PubMedCrossRefGoogle Scholar
  89. 89.
    Kalluri R. Basement membranes: structure, assembly, and role in tumour angiogenesis. Nat Rev Cancer. 2003;3:422–33.PubMedCrossRefGoogle Scholar
  90. 90.
    Takahashi H. Type IV collagen 7S domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. J Gastroenterol. 2007;42:375–81.PubMedCrossRefGoogle Scholar
  91. 91.
    Kropf J, Gressner AM, Negwer A. Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases. Clin Chem. 1988;34:2026–30.PubMedGoogle Scholar
  92. 92.
    Li F, Zhu CL, Zhang H, Huang H, Wei Q, Zhu X, Cheng XY. Role of hyaluronic acid and laminin as serum markers for predicting significant fibrosis in patients with chronic hepatitis B. Braz J Infect Dis. 2012;16:9–14.PubMedGoogle Scholar
  93. 93.
    Leroy V. Other non-invasive markers of liver fibrosis. Gastroenterol Clin Biol. 2008;32(6 Suppl):52–7.PubMedCrossRefGoogle Scholar
  94. 94.
    Halfon P, Bourlière M, Pénaranda G, et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol. 2005;4:6.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Körner T, Kropf J, Gressner AM. Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. J Hepatol. 1996;25(5):684–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Geramizadeh B, Janfeshan K, Saberfiroozi M. Serum hyaluronic acid as a noninvasive marker of hepatic fibrosis in chronic hepatitis B. Saudi J Gastroenterol. 2008;14(4):174–7.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Montazeri G, Estakhri A, Mohamadnejad M, et al. Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol. 2005;5:32.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Guéchot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem. 1996;42:558–63.PubMedGoogle Scholar
  99. 99.
    Montazeri G, Estakhri A, Mohamadnejad M, et al. Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol. 2005;5:Article 32.CrossRefGoogle Scholar
  100. 100.
    Vizzutti F, Arena U, Nobili V, et al. Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease. Ann Hepatol. 2009;8(2):89–94, 2009PubMedCrossRefGoogle Scholar
  101. 101.
    Naveau S, Raynard B, Ratziu V, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol. 2005;3(2):167–74.PubMedCrossRefGoogle Scholar
  102. 102.
    Lausen M, Lynch N, Schlosser A, Tornoe I, Saekmose SG, et al. Microfibril-associated protein 4 is present in lung washings and binds to the collagen region of lung surfactant protein D. J Biol Chem. 1999;274:32234–40.PubMedCrossRefGoogle Scholar
  103. 103.
    Schlosser A, Thomsen T, Shipley JM, Hein PW, Brasch F, et al. Microfibril-associated protein 4 binds to surfactant protein A (SP-A) and colocalizes with SP-A in the extracellular matrix of the lung. Scand J Immunol. 2006;64:104–16.PubMedCrossRefGoogle Scholar
  104. 104.
    Molleken C, Sitek B, Henkel C, Poschmann G, Sipos B, et al. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology. 2009;49:1257–66.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Molleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, et al. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology. 2009;49(4):1257–66.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, et al. Dual expression of matrix protease −2 and membrane type I-matrix proteinase in fibrotic human livers. Hepatology. 1997;26:1521–9.PubMedCrossRefGoogle Scholar
  107. 107.
    Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as non invasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci. 1999;44:624–30.PubMedCrossRefGoogle Scholar
  108. 108.
    Pinzani M, Marra F. Cytokine receptors and signalling in hepatic stellate cells. Semin Liver Dis. 2001;21(3):397–416.PubMedCrossRefGoogle Scholar
  109. 109.
    Harada KI, Shiota G, Kawasaki H. Transforming growth factor α and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver. 1999;19(4):318–25.PubMedCrossRefGoogle Scholar
  110. 110.
    Nelson DR, Gonzalez PRP, Qian K, et al. Transforming growth factor-β1 in chronic hepatitis C. J Viral Hepat. 1997;4(1):29–35.PubMedCrossRefGoogle Scholar
  111. 111.
    Kanzler S, Baumann M, Schirmacher P, et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-β. J Viral Hepat. 2001;8(6):430–7.PubMedCrossRefGoogle Scholar
  112. 112.
    Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. 2008;134(6):1670–81.PubMedCrossRefGoogle Scholar
  113. 113.
    Gressner OA, Gressner AM. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int. 2008;28:1065–79.PubMedCrossRefGoogle Scholar
  114. 114.
    Pinzami M, Milani S, Herbst H, et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol. 1996;148:785–800.Google Scholar
  115. 115.
    Ikura Y, Morimoto H, Ogami M, et al. Expression of platelet-derived growth factor and its receptor in livers of patients with chronic liver disease. J Gastroenterol. 1997;32:496–501.PubMedCrossRefGoogle Scholar
  116. 116.
    Zhou J, Deng Y, Yan L, Zhao H, Wang G. Serum platelet derived growth factor BB levels: a potential biomarker for the assessment of liver fibrosis in patients with chronic hepatitis B. Int J Infect Dis. 2016;49:94–9.PubMedCrossRefGoogle Scholar
  117. 117.
    Yoshida S, Ikenaga N, Liu SB, et al. Extra hepatic platelet-derived growth factor-beta, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology. 2014;147:1378–92.PubMedCrossRefGoogle Scholar
  118. 118.
    Susanne GS, Belinda M, Peer BC, et al. Microfibrillar associated protein 4: a potential biomarker for screening for liver fibrosis in a mixed patient cohort. PLoS One. 2015;10(10):e0140418.CrossRefGoogle Scholar
  119. 119.
    Molleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, Warscheid B, et al. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology. 2009;49(4):1257–66.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Christian M, Barbara S, Corinna H, et al. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology. 2009;49:1257–66.CrossRefGoogle Scholar
  121. 121.
    Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology. 2002;40:403–39.PubMedCrossRefGoogle Scholar
  122. 122.
    Yilmaz Y, Dolar E, Ulukaya E, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from non-alcoholic steatohepatitis. World J Gastroenterol. 2007;13:837–44.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Yang M, Xu D, Liu Y, et al. Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis. PLoS One. 2015;10(6):e0131664.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Feldstein A, Alkhouri N, De Vito R, Alisi A, Lopez R, Nobili V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol. 2013;108:1526–31.PubMedCrossRefGoogle Scholar
  125. 125.
    Juran BD, Lazaridis KN. Genomics and complex liver disease: challenges and opportunities. Hepatology. 2006;44:1380–90.PubMedCrossRefGoogle Scholar
  126. 126.
    Chalasani N, Guo X, Loomba R, et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology. 2010;139:1567–76. e1561–1566PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Thomasson HR, Crabb DW, Edenberg HJ, Li TK, Hwu HG, Chen CC, Yeh EK, Yin SJ. Low frequency of the ADH2∗2 allele among atayal natives of Taiwan with alcohol use disorders. Alcohol Clin Exp Res. 1994;18:640–3.PubMedCrossRefGoogle Scholar
  128. 128.
    Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology. 2007;46:297–306.PubMedCrossRefGoogle Scholar
  129. 129.
    Huang H, Shiffman ML, Cheung RC, Layden T, Friedman S, Abar OT, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology. 2006;130:1679–87.PubMedCrossRefGoogle Scholar
  130. 130.
    Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DHG, Shorthouse C, Purdie DM, Jonsson JR. Host genetic factors influence disease progression in chronic hepatitis. Hepatology. 2000;31:828–33.PubMedCrossRefGoogle Scholar
  131. 131.
    Gewaltig J, Mangasser-Stephan K, Gartung C, Biesterfeld S, Gressner AM. Association of polymorphisms of the transforming growth factor-1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta. 2002;316:83–94.PubMedCrossRefGoogle Scholar
  132. 132.
    Tag CG, Mengsteab S, Hellerbrand C, Lammert F, Gressner AM, Weiskirchen R. Analysis of the transforming growth factor-beta1 (TGF-beta1) codon 25 gene polymorphism by Light Cycler-analysis in patients with chronic hepatitis C infection. Cytokine. 2003;24:173–81.PubMedCrossRefGoogle Scholar
  133. 133.
    Wang H, Mengsteab S, Tag CG, Gao CF, Hellerbrand C, Lammert F, Gressner AM, Weiskirchen R. Transforming growth factor-beta1 polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol. 2005;11:1929–36.PubMedPubMedCentralCrossRefGoogle Scholar
  134. 134.
    Osterreicher CH, Datz C, Stickel F, Hellerbrand C, Penz M, Hofer H, Wrba F, Penner E, Schuppan D, Ferenci P. TGF-[beta]1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine. 2005;31:142–8.PubMedCrossRefGoogle Scholar
  135. 135.
    Hall RA, Liebe R, Hochrath K, et al. Systems genetics of liver fibrosis: identification of fibrogenic and expression quantitative trail loci in the BXD murine reference population. PLoS ONE. 2014;9(2):e89279.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Lopez-Rodriguez R, Hernandez-Bartolome A, Borque MJ, et al. Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C. PLoS One. 2017;12(7):e0180927.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5.PubMedCrossRefGoogle Scholar
  138. 138.
    Kren BT, Wong PY, Sarver A, Zhang X, Zeng Y, Steer CJ. Micro RNAs identified in highly purified liver-derived mitochondria may play a role in apoptosis. RNA Biol. 2009;20:65–72.CrossRefGoogle Scholar
  139. 139.
    Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in patients with chronic hepatitis C virus infection. Science. 2010;327:198–201.PubMedCrossRefGoogle Scholar
  140. 140.
    Szabo G, Shashi B. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013;10(9):542–52.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Smith BC, Grove J, Guzail MA, Day CP, Daly AK, Burt AD, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology. 1998;27:1695–9.PubMedCrossRefGoogle Scholar
  142. 142.
    Erhardt A, Maschner-Olberg A, Mellenthin C, Kappert G, Adams O, Donner A, et al. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol. 2003;38:335–42.PubMedCrossRefGoogle Scholar
  143. 143.
    Geier A, Reugels M, Weiskirchen R, Wasmuth HE, Dietrich CG, Siewert E, et al. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C. Liver Int. 2004;24:285–94.PubMedCrossRefPubMedCentralGoogle Scholar
  144. 144.
    Cal’es P, Lain’e F, Boursier J, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol. 2009;50(1):165–73.CrossRefGoogle Scholar
  145. 145.
    Cal’es P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005;42(6):1373–81.CrossRefGoogle Scholar
  146. 146.
    Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704–13.PubMedCrossRefPubMedCentralGoogle Scholar
  147. 147.
    Valva P, Casciato P, Diaz Carrasco JM, Gadano A, Galdame O, Galoppo MC, et al. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection. PLoS One. 2011;6:e23218.PubMedPubMedCentralCrossRefGoogle Scholar
  148. 148.
    Valva P, Casciato P, Carol Lezama C, Galoppo M, Gadano A, Galdame O, et al. Serum apoptosis markers related to liver damage in chronic hepatitis c: sfas as a marker of advanced fibrosis in children and adults while m30 of severe steatosis only in children. PLoS One. 2013;8(1):e53519.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Patel K, Gordon S, Jacobson I, et al. Evaluation of a panel of noninvasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol. 2004;41:935–42.PubMedCrossRefGoogle Scholar
  150. 150.
    Kelleher TB, Mehta H, Bhaskar R, et al. Prediction of hepatic fibrosis in HIV/HCV coinfected patients using serum fibrosis markers: The SHASTA index. J Hepatol. 2005;43(1):78–84.PubMedCrossRefGoogle Scholar
  151. 151.
    Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704–13.PubMedCrossRefPubMedCentralGoogle Scholar
  152. 152.
    Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Non-invasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology. 2008;47(2):455–60.PubMedCrossRefGoogle Scholar
  153. 153.
    Toson EA, Shiha GE, Abdelgaleel AE. Fibrogenic/angiogenic linker for non-invasive assessment of hepatic fibrosis staging in chronic hepatitis C among Egyptian patients. Ann Hepatol. 2017;16(6):862–73.PubMedCrossRefGoogle Scholar
  154. 154.
    Shiha G, Ibrahim A, Helmy A, Sarin S, Omata M, Kumar A, et al. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int. 2017;11:1–30.PubMedCrossRefGoogle Scholar
  155. 155.
    European Association for the Study of the Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237–64.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Gamal Shiha
    • 1
    • 2
  • Nasser Mousa
    • 3
  1. 1.Department of Internal Medicine and HepatologyMansoura UniversityMansouraEgypt
  2. 2.Egyptian Liver Research Institute and Hospital (ELRIH), SherbinEl-MansouraMansouraEgypt
  3. 3.Departments of Tropical MedicineMansoura UniversityMansouraEgypt

Personalised recommendations